131 related articles for article (PubMed ID: 872117)
1. Immunological responsiveness in patients with bladder cancer.
Fahey JL; Brosman S; Dorey F
Cancer Res; 1977 Aug; 37(8 Pt 2):2875-8. PubMed ID: 872117
[TBL] [Abstract][Full Text] [Related]
2. Immunocompetence of patients with transitional cell carcinoma as measured by dinitrochlorobenzene skin tests and in vitro lymphocyte function.
Bean MA; Schellhammer PS; Herr HW; Pinsky CM; Whitmore WF
Natl Cancer Inst Monogr; 1978 Dec; (49):111-4. PubMed ID: 155219
[TBL] [Abstract][Full Text] [Related]
3. Skin tests with soluble tumor membrane antigens in patients with transitional cell cancers.
Hollinshead AC
Natl Cancer Inst Monogr; 1978 Dec; (49):255-6. PubMed ID: 748779
[TBL] [Abstract][Full Text] [Related]
4. [Adjuvant local BCG-immunotherapy in patients with urothel cancer of the bladder (author's transl)].
Flamm J; Grof F
Wien Med Wochenschr; 1981 Oct; 131(20):501-6. PubMed ID: 7314632
[TBL] [Abstract][Full Text] [Related]
5. Depression of the generation of cell-mediated cytotoxicity by macrophage-like suppressor cells in bladder carcinoma patients.
Spina CA; Dorey F; Vescera C; Brosman S; Fahey JL
Cancer Res; 1981 Nov; 41(11 Pt 1):4324-30. PubMed ID: 6458353
[TBL] [Abstract][Full Text] [Related]
6. [Immunologic indices of patients with transitional cell carcinoma of the urinary bladder].
Bkhatta AD; Makhlin NV
Urol Nefrol (Mosk); 1984; (2):67-70. PubMed ID: 6372193
[No Abstract] [Full Text] [Related]
7. [Changes in the mechanical integration of transitional epithelial cells and in the immune status of patients with bladder tumors].
Bocharova OA; Serebriakova RV; Golubeva VA; Figurin KM; Bukharkin BV; Bodrova NB; Matveev BP; Baryshnikov AIu
Urol Nefrol (Mosk); 1994; (3):27-30. PubMed ID: 8079407
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of host immunocompetence in urologic cancer patients.
Catalona WJ; Smolev JK; Harty JI
J Urol; 1975 Dec; 114(6):922-6. PubMed ID: 1195475
[TBL] [Abstract][Full Text] [Related]
9. Leukocyte migration inhibition in vitro in bladder carcinoma.
Lavergne JA; Lamm DL; Radwin HM; Harrington JT
Cancer Res; 1979 Jun; 39(6 Pt 1):1985-8. PubMed ID: 445398
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
[TBL] [Abstract][Full Text] [Related]
11. Correlation among host immunocompetence and tumor stage, tumor grade and vascular permeation in transitional carcinoma.
Catalona WJ; Chretien PB
J Urol; 1973 Nov; 110(5):526-8. PubMed ID: 4750895
[No Abstract] [Full Text] [Related]
12. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
Mizutani Y; Okada Y; Terachi T; Yoshida O
J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer.
Fokdal L; Høyer M; von der Maase H
Acta Oncol; 2004; 43(8):749-57. PubMed ID: 15764221
[TBL] [Abstract][Full Text] [Related]
14. [Results of long-term treatment of inoperable cancer of the bladder with cisplatin and concurrent irradiation: prognostic factors of local control and survival].
Chauvet B; Félix-Faure C; Davin JL; Choquenet C; Alfonsi M; Reboul F
Cancer Radiother; 1998 Apr; 2 Suppl 1():85s-91s. PubMed ID: 9749086
[TBL] [Abstract][Full Text] [Related]
15. In vivo skin test in carcinoma bladder.
Gupta NP; Rajagopal V; Malaviya AN; Singh SM
Indian J Cancer; 1984 Nov-1985 Jan; 21(5-6):163-5. PubMed ID: 6545227
[No Abstract] [Full Text] [Related]
16. Immunologic evaluation of patients with cancer by delayed hypersensitivity reactions.
Burdick JF; Wells SA; Herberman RB
Surg Gynecol Obstet; 1975 Nov; 141(5):779-94. PubMed ID: 128144
[TBL] [Abstract][Full Text] [Related]
17. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
18. Some immunological considerations relevant to the study of human bladder cancer.
Bean MA
Cancer Res; 1977 Aug; 37(8 Pt 2):2879-84. PubMed ID: 326394
[TBL] [Abstract][Full Text] [Related]
19. Immunological status of patients with bladder cancers (transitional cell tumours).
Frantz P; Khoury S; Kuss R
Prog Clin Biol Res; 1984; 162A():201-8. PubMed ID: 6385023
[No Abstract] [Full Text] [Related]
20. Immunologic reduction of bladder cancer recurrence rate.
Olsson CA; Chute R; Rao CN
Trans Am Assoc Genitourin Surg; 1973; 65():66-72. PubMed ID: 4763514
[No Abstract] [Full Text] [Related]
[Next] [New Search]
